JPMorgan Chase & Co. Begins Coverage on Aktis Oncology (NASDAQ:AKTS)

Analysts at JPMorgan Chase & Co. assumed coverage on shares of Aktis Oncology (NASDAQ:AKTS) in a research note issued on Tuesday. The firm set an “overweight” rating and a $30.00 price target on the technology company’s stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 36.49% from the stock’s current price.

Several other research analysts have also recently issued reports on AKTS. Wall Street Zen upgraded shares of Aktis Oncology to a “hold” rating in a report on Saturday, January 17th. Leerink Partners started coverage on shares of Aktis Oncology in a research report on Tuesday. They issued an “outperform” rating and a $31.00 price target for the company. Bank of America initiated coverage on shares of Aktis Oncology in a research note on Tuesday. They set a “buy” rating and a $34.00 price objective on the stock. Finally, TD Cowen assumed coverage on shares of Aktis Oncology in a research note on Tuesday. They issued a “buy” rating for the company. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $31.67.

Aktis Oncology Trading Up 8.5%

Shares of AKTS stock opened at $21.98 on Tuesday. Aktis Oncology has a twelve month low of $18.52 and a twelve month high of $29.16.

Insider Activity

In other Aktis Oncology news, Director Helen Susan Kim purchased 835,000 shares of Aktis Oncology stock in a transaction dated Monday, January 12th. The shares were acquired at an average cost of $18.00 per share, with a total value of $15,030,000.00. Following the completion of the transaction, the director owned 5,671,825 shares in the company, valued at approximately $102,092,850. This trade represents a 17.26% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Ansbert Gadicke acquired 1,112,777 shares of the firm’s stock in a transaction dated Monday, January 12th. The shares were acquired at an average price of $18.00 per share, with a total value of $20,029,986.00. Following the acquisition, the insider owned 10,260,064 shares in the company, valued at approximately $184,681,152. The trade was a 12.17% increase in their position. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 6,117,776 shares of company stock worth $110,119,968 over the last 90 days. 3.30% of the stock is currently owned by insiders.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.